Healthcare Industry News: Novo Nordisk
News Release - May 10, 2006
Novo Nordisk Appoints Edward Williams as Vice President of BiopharmaceuticalsAssumes position as new member of Executive Team
PRINCETON, N.J., May 10 (HSMN NewsFeed) -- Novo Nordisk, a leader in breakthrough hemostasis research and treatment, today announced the appointment of Edward L. Williams as vice president of biopharmaceuticals and as a new member of the Executive Team. In this leadership position, Williams will build and execute the business strategies for the biopharmaceuticals business unit and will set direction for the company's biopharmaceutical products, including hemostasis, growth hormone therapy, and hormone therapy for women.
"At Novo Nordisk, we are committed to hiring the best in the industry to advance the health and quality of life for the patients we serve, and Eddie is a perfect example of the caliber we seek. Eddie's expertise will help further the full potential of Novo Nordisk's biopharmaceuticals unit and cement Novo Nordisk's position as a leader in breakthrough science and medicine," said Martin Soeters, president of Novo Nordisk USA. "Eddie's superior performance in developing specialty product portfolios and leading results-generating marketing and sales organizations will enable us to continue our success within this division."
Williams brings 26 years of industry experience to Novo Nordisk. Most recently, he served as vice president of sales for the respiratory and dermatology business unit at Novartis Pharmaceuticals Corporation where he managed the commercial growth of several products. While at Novartis, Williams led a sales force of 770 and was internally recognized for his outstanding leadership. He was also a multiple winner of US and global awards in previous companies including 2004 "Achiever of the Year" by the National Sales Network and executive sponsor for culture initiatives.
"I am thrilled to be a part of the Novo Nordisk team and am excited to be instrumental in the company's goal to be a recognized leader in biopharmaceuticals. I continue to be impressed by Novo Nordisk's passion and commitment to improving patients' quality of life," said Williams. "I have seen the benefits and difference biopharmaceuticals are making in people's lives and I want to be a part of the continued solutions. As a member of the Executive Team, I look forward to contributing to Novo Nordisk's next level of success while helping to maintain Novo Nordisk's entrepreneurial and inclusive culture."
As vice president of biopharmaceuticals, Williams will expand the biopharmaceutical product portfolio and execute strategies to ensure continued profitability and sustainability. He also will lead efforts to explore the full potential of Novo Nordisk's biopharmaceuticals projects as well as identify new drug targets and projects. Further, Williams will focus on putting the correct structure, processes, and support in place to strengthen Novo Nordisk's marketing, sales, and medical affairs departments. Williams will report directly to the president of Novo Nordisk and will be a member of the ten-person newly expanded Executive Team.
In the United States, Novo Nordisk has seen tremendous growth within the past few years, more than doubling its workforce since 2000. During that time, the company has heightened its focus on Novo Nordisk's Triple Bottom Line, which fosters economic success while protecting the well-being of its customers, the community, the environment, and particularly its employees. To this end, the organization's "My Company" culture promotes a work environment where attention is paid to the human behind the employee, where regular and honest communication is encouraged and valued, and where major accomplishments and small achievements alike are celebrated.
Novo Nordisk is a healthcare company with an 80-year history of innovation and achievement in diabetes care. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs approximately 22,000 full- time employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit http://novonordisk.com; for United States information, visit http://novonordisk-us.com.
Source: Novo Nordisk
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.